Cargando…
Interleukin 2-Based Fusion Proteins for the Treatment of Cancer
Interleukin 2 (IL-2) plays a fundamental role in both immune activation and tolerance and has revolutionized the field of cancer immunotherapy since its discovery. The ability of IL-2 to mediate tumor regression in preclinical and clinical settings led to FDA approval for its use in the treatment of...
Autores principales: | MacDonald, Alana, Wu, T.-C., Hung, Chien-Fu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592747/ https://www.ncbi.nlm.nih.gov/pubmed/34790830 http://dx.doi.org/10.1155/2021/7855808 |
Ejemplares similares
-
Delivery of IL-2 to the T Cell Surface Through Phosphatidylserine Permits Robust Expansion of CD8 T Cells
por: MacDonald, Alana, et al.
Publicado: (2021) -
Interleukin-21 in cancer immunotherapy: Friend or foe?
por: Stolfi, Carmine, et al.
Publicado: (2012) -
Localization of Salmonella and albumin-IL-2 to the tumor microenvironment augments anticancer T cell immunity
por: Kung, Yu-Jui, et al.
Publicado: (2022) -
Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor- mediated action of a diphtheria toxin-related interleukin 2 fusion protein
Publicado: (1988) -
A recombinant single chain antibody interleukin-2 fusion protein.
por: Savage, P., et al.
Publicado: (1993)